HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $36 to $40.
Owens Corning For 4Q23 Expects Overall Performance To Result In Net Sales Slightly Below Last Year, While Generating Mid-Teen EBIT Margins
Fourth-Quarter 2023 Outlook
The key economic factors that impact the company's businesses are residential repair and remodeling activity, U.S. housing starts, global commercial construction activity, and
